Navigation Links
Exelixis Announces June 25 Webcast of Presentation at the Piper Jaffray Europe Conference
Date:6/18/2008

SOUTH SAN FRANCISCO, Calif., June 18 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that Frank Karbe, executive vice president and chief financial officer at Exelixis, will present at the Piper Jaffray Europe Conference at 3:40 a.m. PT/6:40 a.m. ET/11:40 a.m. London, UK time on Wednesday, June 25, 2008. Mr. Karbe will discuss updates to the company's development pipeline and corporate strategy.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's website at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
(Date:1/22/2015)... Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... on advanced wound care, announces that AMNIOEXCEL® and ... been added to the Premier, Inc. Regenerative Skin ... for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which ...
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... NanoLogix, Inc. (OTC:,NNLX - News) a nano-biotechnology ... company events:, NanoLogix personnel are manning a ... in Sacramento this week, with the company being,represented ... will be,presenting in the Exhibition Hall today, March ...
... With Needle-free Vaccine Technology and ... Bird Flu Clinical Program, Webcast/teleconference ... IRVING, Texas, March 31 Carrington,Laboratories, Inc. (OTC Bulletin Board: CARN) ... million, or ($0.90) per basic and,diluted share, for the year ended ...
... MONMOUTH JUNCTION, N.J., March 31 Transave, ... inhaled,pharmaceuticals for the site-specific treatment of serious ... an aggregate of $35 million pursuant to,its ... Company,s,Board are Richard Kollender from Quaker BioVentures ...
Cached Biology Technology:NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update 2NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update 3Carrington Reports 2007 Financial Results 2Carrington Reports 2007 Financial Results 3Carrington Reports 2007 Financial Results 4Carrington Reports 2007 Financial Results 5Carrington Reports 2007 Financial Results 6Carrington Reports 2007 Financial Results 7Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing 2Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing 3
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a market ... appointed Steve Gerber to the new role of ... responsible for leading development of mobile platforms and wearable solutions ... success and innovation in the semiconductor industry to his role ...
(Date:12/22/2014)... 2014 Holiday Season may be the brightest ever for ... the long anticipated floodgates for consumer biometrics may finally ... phones, tablets, and wearable mobile devices that incorporate biometrics ... with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 Based ... 5S, Samsung introduces for the first time a fingerprint ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... entomologists will meet June 16-19, 2013 at the Best Western ... South Dakota as the Entomological Society of America,s North Central ... will include: , Forests pests, such as the ... Agricultural insect pests such as the western corn rootworm, the ...
... Paris, France: The group of genetic conditions known as ... always fatal, in the case of affected children at an ... gait, and poor co-ordination of hands, speech and eye movements, ... researchers from France and the US have found a new ...
... (June 9, 2013) Researchers at Whitehead Institute have ... the drugs that are used to increase red blood ... including those resulting from trauma, sepsis, malaria, kidney dialysis, ... capable of increasing this protein,s production without causing the ...
Cached Biology News:Interferon-beta aids balance and movement in mice with spinocerebellar ataxia 7 2Interferon-beta aids balance and movement in mice with spinocerebellar ataxia 7 3Scientists identify potential drug target for treatment-resistant anemias 2
... Wash Pack provides optimized blocking and ... Quality Clarifier: Ready-to-use wash solutions have ... APS Coated Slides for Microarrays (Product ... Blocking Buffer: 1L • Microarray Post ...
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
Mouse monoclonal antibody raised against a partial recombinant NEK2. NCBI Entrez Gene ID = NEK2...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Biology Products: